Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leisha A Emens

Showing results (61-70 of 114) with videos related to

Pageof 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)|June 18, 2017
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscapeLeisha A Emens, Paolo A Ascierto, Phillip K Darcy, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockadeTheinmozhi Arulraj, Hanwen Wang, Atul Deshpande, et al.
International Immunopharmacology|March 11, 2017
Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivoMelek M E Sunay, Jeremy B Foote, James M Leatherman, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 28, 2024
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockadeTheinmozhi Arulraj, Hanwen Wang, Atul Deshpande, et al.
Human Pathology|December 31, 2017
Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancerLaureen S Ojalvo, Elizabeth D Thompson, Tian-Li Wang, et al.
Human Gene Therapy|January 17, 2018
Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer TherapyChien-Fu Hung, Xuequn Xu, Linhong Li, et al.
Molecular Imaging|June 13, 2019
Development of [<sup>18</sup>F]FPy-WL12 as a PD-L1 Specific PET Imaging PeptideWojciech G Lesniak, Ronnie C Mease, Samit Chatterjee, et al.
Journal for Immunotherapy of Cancer|March 22, 2025
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapyThomas U Marron, Jason J Luke, Brianna Hoffner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic miceMatthew E Wolpoe, Eric R Lutz, Anne M Ercolini, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 22, 2017
PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breastElizabeth D Thompson, Janis M Taube, Rebecca J Asch-Kendrick, et al.
Pageof 12

Showing results (61-70 of 114) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|June 18, 2017
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscapeLeisha A Emens, Paolo A Ascierto, Phillip K Darcy, et al.
Biorxiv : the Preprint Server for Biology|June 3, 2024
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockadeTheinmozhi Arulraj, Hanwen Wang, Atul Deshpande, et al.
International Immunopharmacology|March 11, 2017
Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivoMelek M E Sunay, Jeremy B Foote, James M Leatherman, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 28, 2024
Virtual patient analysis identifies strategies to improve the performance of predictive biomarkers for PD-1 blockadeTheinmozhi Arulraj, Hanwen Wang, Atul Deshpande, et al.
Human Pathology|December 31, 2017
Tumor-associated macrophages and the tumor immune microenvironment of primary and recurrent epithelial ovarian cancerLaureen S Ojalvo, Elizabeth D Thompson, Tian-Li Wang, et al.
Human Gene Therapy|January 17, 2018
Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer TherapyChien-Fu Hung, Xuequn Xu, Linhong Li, et al.
Molecular Imaging|June 13, 2019
Development of [<sup>18</sup>F]FPy-WL12 as a PD-L1 Specific PET Imaging PeptideWojciech G Lesniak, Ronnie C Mease, Samit Chatterjee, et al.
Journal for Immunotherapy of Cancer|March 22, 2025
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapyThomas U Marron, Jason J Luke, Brianna Hoffner, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 7, 2003
HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic miceMatthew E Wolpoe, Eric R Lutz, Anne M Ercolini, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 22, 2017
PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breastElizabeth D Thompson, Janis M Taube, Rebecca J Asch-Kendrick, et al.
Pageof 12